Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> GLAXOSMITHKLINE Latest News

18 HOURS AGO - Benzinga

A Must Read - Share

GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia

GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).1

Tags: GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) Indication For Use In Patients With Severe Aplastic Anaemia,  Glaxosmithkline Latest News

21 HOURS AGO - TheStreet

A Must Read - Share

4 Foreign Blue-Chip Stocks With 4% Dividend Yields to Buy

NEW YORK (TheStreet) -- What do China Petroleum & Chemical , Empresa Nacional de Electricidad , GlaxoSmithKline and Westpac Banking Corporation have in common? They are foreign, blue-chip stocks paying 4% dividends, far superior to comparableaAmerican stocks such as Exxon Mobil , Edison International , Bristol-Myers Squibb and Bank of America . Read More: 10 Stocks Carl Icahn Loves in ...

Tags: 4 Foreign Blue-Chip Stocks With 4% Dividend Yields to Buy,  Glaxosmithkline Latest News

AUG 25, 2014 - Zacks Investment Research

A Must Read - Share

AUG 25, 2014 - TheStreet

A Must Read - Share

Biotechs Rise After InterMune Acquired by Roche

NEW YORK (TheStreet) -- Shares of a number of biopharmaceutical companies are climbing after drug maker Roche agreed to buy its smaller peer, Intermunea . InterMune focuses on developing treatments for respiratory and orphan fibrotic diseases. WHAT'S NEW: Roche agreed to buy InterMune for $74 per share in an all-cash transaction, the companies announced yesterday. InterMune's stock closed at $53.80 ...

Tags: Biotechs Rise After InterMune Acquired by Roche,  Glaxosmithkline Latest News

AUG 25, 2014 - TheStreet

A Must Read - Share

Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal

NEW YORK (TheStreet) --aTheStreet'saJim CramerasaysaRocheacalled itsapurchase ofaInterMunea a "bolt-on" acquisition. Cramer says the $8.3 billion bid signifies that big pharmaceutical companies are thinking big even as Roche calls this a "bolt-on" acquisition. Cramer notes in the old days, "bolt on" would have meant anything less than $1 billion. Cramer calls this deal important because so many biotech companies are losing ...

Tags: Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal,  Glaxosmithkline Latest News